US-based diagnostic solutions provider Quidel has signed definitive agreements to buy Triage assets from point-of-care (POC) diagnostics firm Alere for around $400m and an additional $40m in contingent consideration.

The agreement includes the Triage MeterPro cardiovascular (CV) and toxicology assets, real estate for the Triage facilities at San Diego, US, and the B-type Naturietic Peptide (BNP) assay business.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal is expected to diversify Quidel’s overall business and bolster its presence in the POC market, while the combination of businesses will offer rapid diagnostics in critical care settings.

Alere is divesting the assets to obtain antitrust approvals that are required for its approximately $5.3bn acquisition by Abbott, estimated to be completed by the end of the third quarter of this year.

Quidel president and CEO Douglas Bryant said: “The Triage acquisition significantly stabilises our quarterly revenue profile and enhances our geographic and product diversity, with substantial expansion opportunities in new markets.

See Also:

"The Triage acquisition significantly stabilises our quarterly revenue profile and enhances our geographic and product diversity, with substantial expansion opportunities in new markets."

“We believe there are substantial benefits to be realised as we bring these strong organisations together, further establishing Quidel’s platform for growth and shareholder value creation opportunities.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Quidel anticipates that the footprint of Triage MeterPro instruments in the country will complement its base of Sofia and Solana platforms in the hospital segment, while the Triage MeterPro system will offer access to its cardiac biomarker segment.

The firm intends to commercialise the Triage MeterPro products and BNP assays via direct sales force and distributors.

Expected to be closed by September, the Triage assets deal is subject to the completion of Abbott’s transaction, antitrust approvals and other customary closing conditions.